Ex vivo expanded allogeneic cord blood progenitor cell transplantation with a non-myeloablative conditioning regimen would cure autoimmune diseases.
Loss of self-tolerance is the basis for autoimmune disease. Autologous as well as allogeneic stem cell transplantation is increasingly being considered and used for therapy of autoimmune disease. Non-myeloablative conditioning has been shown in the context of malignant diseases to be feasible. Cord blood transplantation has been associated with significantly less graft-versus-host disease (GVHD) than other forms of allotransplantation. Ex-vivo expansion of this limited resource is increasingly becoming feasible. It is being hypothesized that ex-vivo expanded cord blood progenitor cell transplantation using a non-myeloablative conditioning regimen would be curative in autoimmune diseases.
Sastry
P S
PS
Visakhapatnam (A.P.), India.
D001327:Autoimmune Diseases / Q000628:therapy*; D005312:Fetal Blood / Q000166:cytology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous